Unicycive Therapeutics Inc. Common Stock UNCY · Stock Open Unicycive Therapeutics Inc. Common Stock in new tab
Unicycive Therapeutics Inc. Common Stock Analysis (UNCY)
Is Unicycive Therapeutics Inc. Common Stock a good investment? Unicycive Therapeutics Inc. Common Stock (UNCY) is currently trading at 4.80 USD. Market analysts have a consensus price target of 29.60 USD. This suggests a potential upside from current levels.
Earnings Schedule: Unicycive Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is 1.66.
Investor FAQ
Does Unicycive Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Unicycive Therapeutics Inc. Common Stock?
Unicycive Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.75.
Company Profile
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
| Split Date | Split Ratio to 1 |
|---|---|
| June 20, 2025 | 1:10 |
Community Discussion